Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.

Saved in:
Bibliographic Details
Title: Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.
Authors: Glorieux FH; Departments of Surgery, Pediatrics and Human Genetics, Shriners Hospitals for Children, McGill University, Montreal, Quebec H4A 0A9, Canada., Langdahl B; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Middle Jutland 8200, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Middle Jutland 8200, Denmark., Chapurlat R; Inserm UMR 1033, Edouard Herriot Hospital, 69372 Lyon cedex 08, France., De Beur SJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States., Sutton VR; Department of Molecular & Human Genetics, Baylor College of Medicine & Texas Children's Hospital, Houston, TX 77030, United States., Poole KES; Department of Medicine & Cambridge NIHR Biomedical Research Centre, University of Cambridge, Cambridge CB3 0FA, United Kingdom., Dahir KM; Division of Endocrinology, Vanderbilt University Medical Center, Nashville, TN 37232, United States., Orwoll ES; Division of Endocrinology, Diabetes and Clinical Nutrition, School of Medicine, Oregon Health & Sciences University, Portland, OR 97239, United States., Willie BM; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal H3A 2T5, Canada.; Shriners Hospitals for Children, Montreal, Quebec H4A 0A9, Canada., Mikolajewicz N; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal H3A 2T5, Canada.; Shriners Hospitals for Children, Montreal, Quebec H4A 0A9, Canada., Zimmermann E; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal H3A 2T5, Canada.; Shriners Hospitals for Children, Montreal, Quebec H4A 0A9, Canada., Hosseinitabatabaei S; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal H3A 2T5, Canada.; Shriners Hospitals for Children, Montreal, Quebec H4A 0A9, Canada., Ominsky MS; Ultragenyx Pharmaceutical Inc., Novato, CA 94949, United States., Saville C; ICON Plc, Leopardstown, Dublin D 18, Ireland., Clancy J; Mereo BioPharma, London W16 0QF, United Kingdom., MacKinnon A; Mereo BioPharma, London W16 0QF, United Kingdom., Mistry A; Mereo BioPharma, London W16 0QF, United Kingdom., Javaid MK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Wellington Square, Oxford OX1 2JD, United Kingdom.
Source: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2024 Sep 02; Vol. 39 (9), pp. 1215-1228.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 8610640 Publication Model: Print Cited Medium: Internet ISSN: 1523-4681 (Electronic) Linking ISSN: 08840431 NLM ISO Abbreviation: J Bone Miner Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-4681
DOI:10.1093/jbmr/zjae112